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Abstract 
The role of endothelial dysfunction and oxidative stress in the pathogenesis of cardiac 
syndrome X has recently been recognised. Allopurinol has previously been shown to 
improve endothelial dysfunction, reduce oxidative stress burden and improve myocardial 
efficiency. In this ‘proof of concept’ study, we investigated the effect of allopurinol on 
exercise capacity, coronary and peripheral endothelial function, and serum B-type 
natriuretic peptide (BNP: a marker of cardiac function and myocardial ischaemia) in 
patients with cardiac syndrome X. 
 
Methods and Results 
This study was a randomised, double-blind, placebo-control crossover trial. Nineteen 
patients (mean age 59±10 years, 11 women & 8 men) with cardiac syndrome X were 
randomised to a 6-week treatment with either allopurinol (600mg/day) or placebo. After 
4 weeks of washout period, they were crossed over to the other arm. Outcomes 
measured at baseline and after treatment were maximum exercise time (ET) derived 
from Bruce protocol exercise treadmill test, serum BNP measurement, coronary flow 
reserve (CFR) as assessed by measuring response of flow velocity in the left anterior 
descending artery to adenosine and flow-mediated vasodilatation of the brachial artery 
(FMD). Allopurinol significantly reduced serum uric acid levels when compared with 
placebo (-48±24% vs 1·9±11%, p<0.001). There was no significant difference in 
maximum ET, CFR and FMD between allopurinol and placebo. However, there was a 
trend that allopurinol reduced serum BNP when compared to placebo [-8% (interquartile 
range -22 to 65%) vs 44% (interquartile range -18 to 140%); p= 0·07). 
Conclusion 
In patients with cardiac syndrome X, high dose allopurinol did not improve exercise 
capacity, coronary or peripheral endothelial function.  
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Introduction 
Patients with cardiac syndrome X (typical anginal-like chest pain and normal coronary 
arteriograms) represent a heterogeneous syndrome, which encompasses different 
pathogenic mechanisms{ ADDIN EN.CITE 
<EndNote><Cite><Author>Kaski</Author><Year>2004</Year><RecNum>4483</RecN
um><DisplayText><style face="superscript">1</style></DisplayText><record><rec-
number>4483</rec-number><foreign-keys><key app="EN" db-
id="sde022erm0xppvetvfyv9pv4azzevtattee9" 
timestamp="1491834224">4483</key></foreign-keys><ref-type name="Journal 
Article">17</ref-type><contributors><authors><author>Kaski, J. 
C.</author><author>Aldama, G.</author><author>Cosin-Sales, 
J.</author></authors></contributors><auth-address>Coronary Artery Disease Research 
Unit, Cardiological Sciences, St George&apos;s Hospital Medical School, London, UK. 
jkaski@sghms.ac.uk</auth-address><titles><title>Cardiac syndrome X. Diagnosis, 
pathogenesis and management</title><secondary-title>Am J Cardiovasc 
Drugs</secondary-title></titles><periodical><full-title>Am J Cardiovasc Drugs</full-
title></periodical><pages>179-
94</pages><volume>4</volume><number>3</number><keywords><keyword>Disease 
Management</keyword><keyword>Humans</keyword><keyword>*Microvascular 
Angina/diagnosis/etiology/therapy</keyword></keywords><dates><year>2004</year></
dates><accession-num>15134470</accession-num><urls><related-
urls><url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMe
d&amp;dopt=Citation&amp;list_uids=15134470 </url></related-
urls></urls></record></Cite></EndNote>}. Many patients have angina pectoris that may 
be due to transient myocardial ischemia{ ADDIN EN.CITE 
<EndNote><Cite><Author>Yaghoubi</Author><Year>2011</Year><RecNum>4473</R
ecNum><DisplayText><style face="superscript">2</style></DisplayText><record><rec-
number>4473</rec-number><foreign-keys><key app="EN" db-
id="sde022erm0xppvetvfyv9pv4azzevtattee9" 
timestamp="1491832744">4473</key></foreign-keys><ref-type name="Journal 
Article">17</ref-type><contributors><authors><author>Yaghoubi, 
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M.</author><author>Arefi, S. H.</author><author>Assadi, 
M.</author></authors></contributors><auth-address>Department of Cardiology, 
Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.</auth-
address><titles><title>Comparison of angiographic with myocardial perfusion 
scintigraphy findings in cardiac syndrome X (CSX)</title><secondary-title>Eur Rev Med 
Pharmacol Sci</secondary-title></titles><periodical><full-title>Eur Rev Med Pharmacol 
Sci</full-title></periodical><pages>1385-
8</pages><volume>15</volume><number>12</number><keywords><keyword>Adult</
keyword><keyword>Calcinosis/diagnosis/etiology</keyword><keyword>Coronary 
Angiography/ methods</keyword><keyword>Coronary 
Stenosis/diagnosis/etiology</keyword><keyword>Female</keyword><keyword>Human
s</keyword><keyword>Male</keyword><keyword>Microvascular Angina/ 
diagnosis/pathology</keyword><keyword>Middle 
Aged</keyword><keyword>Myocardial Perfusion Imaging/ 
methods</keyword></keywords><dates><year>2011</year><pub-
dates><date>Dec</date></pub-dates></dates><isbn>1128-3602 (Print)&#xD;1128-
3602 (Linking)</isbn><accession-num>22288299</accession-
num><urls></urls></record></Cite></EndNote>}. Microvascular abnormalities, caused 
by coronary endothelial dysfunction, maybe responsible for myocardial ischemia in 
patients with cardiac syndrome X{ ADDIN EN.CITE 
<EndNote><Cite><Author>Hurst</Author><Year>2006</Year><RecNum>4474</RecNu
m><DisplayText><style face="superscript">3</style></DisplayText><record><rec-
number>4474</rec-number><foreign-keys><key app="EN" db-
id="sde022erm0xppvetvfyv9pv4azzevtattee9" 
timestamp="1491832875">4474</key></foreign-keys><ref-type name="Journal 
Article">17</ref-type><contributors><authors><author>Hurst, 
T.</author><author>Olson, T. H.</author><author>Olson, L. 
E.</author><author>Appleton, C. P.</author></authors></contributors><auth-
address>Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, Arizona 85259, 
USA.</auth-address><titles><title>Cardiac syndrome X and endothelial dysfunction: 
new concepts in prognosis and treatment</title><secondary-title>Am J 
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Med</secondary-title></titles><periodical><full-title>Am J Med</full-
title></periodical><pages>560-
6</pages><volume>119</volume><number>7</number><keywords><keyword>Angiote
nsin-Converting Enzyme Inhibitors/therapeutic use</keyword><keyword>Endothelium, 
Vascular/ 
physiopathology</keyword><keyword>Estrogens/deficiency/physiology</keyword><key
word>Humans</keyword><keyword>Hydroxymethylglutaryl-CoA Reductase 
Inhibitors/therapeutic 
use</keyword><keyword>Inflammation</keyword><keyword>Ischemia</keyword><key
word>Life 
Style</keyword><keyword>Microcirculation/pathology</keyword><keyword>Microvascu
lar Angina/ drug therapy/ physiopathology</keyword><keyword>Pain 
Threshold</keyword><keyword>Prognosis</keyword><keyword>Risk 
Assessment</keyword></keywords><dates><year>2006</year><pub-
dates><date>Jul</date></pub-dates></dates><isbn>1555-7162 (Electronic)&#xD;0002-
9343 (Linking)</isbn><accession-num>16828624</accession-
num><urls></urls></record></Cite></EndNote>}. Oxidative stress with increased 
production of reactive oxygen species may be one of the main mechanisms contributing 
to this microvascular endothelial dysfunction{ ADDIN EN.CITE 
<EndNote><Cite><Author>Cai</Author><Year>2000</Year><RecNum>172</RecNum>
<DisplayText><style face="superscript">4</style></DisplayText><record><rec-
number>172</rec-number><foreign-keys><key app="EN" db-
id="sde022erm0xppvetvfyv9pv4azzevtattee9" timestamp="0">172</key></foreign-
keys><ref-type name="Journal Article">17</ref-
type><contributors><authors><author>Cai, H.</author><author>Harrison, D. 
G.</author></authors></contributors><auth-address>Division of Cardiology, 
Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.</auth-
address><titles><title>Endothelial dysfunction in cardiovascular diseases: the role of 
oxidant stress</title><secondary-title>Circ Res</secondary-
title></titles><periodical><full-title>Circ Res</full-title></periodical><pages>840-
4</pages><volume>87</volume><number>10</number><keywords><keyword>Animal
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s</keyword><keyword>Cardiovascular 
Diseases/*physiopathology</keyword><keyword>Endothelium, 
Vascular/*physiopathology</keyword><keyword>Humans</keyword><keyword>NADH, 
NADPH Oxidoreductases/metabolism</keyword><keyword>Nitric 
Oxide/metabolism</keyword><keyword>Nitric Oxide 
Synthase/metabolism</keyword><keyword>Nitric Oxide Synthase Type 
III</keyword><keyword>*Oxidative Stress</keyword><keyword>Reactive Oxygen 
Species/metabolism</keyword><keyword>Research Support, Non-U.S. 
Gov&apos;t</keyword><keyword>Research Support, U.S. Gov&apos;t, 
P.H.S.</keyword><keyword>Xanthine 
Oxidase/metabolism</keyword></keywords><dates><year>2000</year><pub-
dates><date>Nov 10</date></pub-dates></dates><accession-
num>11073878</accession-num><urls></urls></record></Cite></EndNote>}. Basal 
superoxide production has been shown to predict future cardiovascular events in this 
patient group{ ADDIN EN.CITE { ADDIN EN.CITE.DATA }} that might suggest an 
important pathophysiological role of oxidative stress.  It has been proposed that the 
improvement in endothelial function observed with combined treatment with a statin and 
angiotensin-converting-enzyme (ACE) inhibitor in patients with cardiac syndrome X may 
be related to a reduction in oxidative stress{ ADDIN EN.CITE { ADDIN EN.CITE.DATA 
}}. However, to the best of knowledge, there have been no studies that have studied the 
direct effects of reducing oxidative stress in patients with cardiac syndrome X.  
 
We have previously  shown that high-dose allopurinol (600mg/day)  improved 
endothelial function, as assessed by forearm venous occlusion plethysmograph in 
patients with chronic heart failure by its ability to reduce oxidative stress, independently 
of any effect on urate levels{ ADDIN EN.CITE { ADDIN EN.CITE.DATA }}. Additionally, 
this high dose allopurinol markedly reduced vascular oxidative stress, as assessed by 
Vitamin C and acetylcholine co-infusion studies. These observations would suggest that 
allopurinol could be used to reduce oxidative stress in cardiac syndrome X. In this study, 
we hypothesized that allopurinol offers dual benefits of improving vascular function and 
reducing myocardial ischemia in patients with cardiac syndrome X. Thus, the objective 
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of this study was to investigate the effects of allopurinol on coronary and peripheral 
endothelial function, serum B-type natriuretic peptides (BNP- a marker of cardiac 
function and myocardial ischemia) and maximum exercise time on treadmill testing in 
patients with cardiac syndrome X.  
 
 
Methods 
Study design 
This was a double-blind, crossover trial comparing the effects of allopurinol and placebo 
on exercise capacity, coronary and peripheral endothelial function and serum BNP 
levels in patients with this syndrome. Patients with cardiac syndrome X were 
randomised to a 6-week treatment with either allopurinol (600mg/day) or placebo. After 
4 weeks of washout period, they were crossed over to the other arm.  
Study patients 
After approval by the Scottish Research Ethics Committee (REC Ref: 07/S1401/103), 
eligible patients provided written informed consent to participate. We recruited patients 
with cardiac syndrome X that had smooth unobstructed epicardial arteries shown on 
coronary angiography at Ninewells Hospital, Dundee.  
Presence of symptoms and evidence of ischemia 
All had on-going typical anginal-type chest pain and at least one objective evidence of 
myocardial ischemia: Documented ≥1 mm of flat ST-segment depression on treadmill 
exercise testing and/or myocardial reversible perfusion abnormalities during adenosine 
stress as assessed by technetium-99m myocardial perfusion imaging.  
All patients underwent pre-trial screening with blood tests and echocardiography. All had 
normal left and right ventricular structure and function with no evidence of significant 
valvular heart disease. All patients had given their written informed consent to 
participate in the study.  
Study Protocol 
Following consent, participants continued on their usual anti-anginal medications that 
remained unchanged during the study period. A Flow Chart of this study is shown in 
Figure 1. In order to allow participants to be familiarised with exercise testing, all 
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underwent treadmill test 1 to 2 weeks prior starting study medication. Thereafter, they 
underwent a baseline exercise stress test and venesection for general hematological 
and biochemical analyses prior starting study medication (allopurinol or placebo). 
Patients were randomly assigned to treatment with either allopurinol or placebo 300 mg 
once daily for the first week, and then up-titrated  to a maintenance dose of 300mg twice 
a day for further 5 weeks (total treatment period=6 weeks).  At the end of this first 
treatment period, patients underwent a 4 weeks wash-out period after which they 
crossed over to the alternate treatment arm for another 6 weeks. Coronary vascular 
function, peripheral endothelial function, exercise testing and serum BNP level were 
carried out at baseline and repeated at the end of each treatment period by investigators 
who were blinded to treatment regimen. All studies were performed in the morning 
following an overnight fast and patients were not allowed to have caffeinated drinks or 
smoke for 12 hours before the tests.  
 
Measurements of interest 
Exercise Treadmill Test.  
The treadmill exercise test (an objective measure of myocardial ischaemia) was 
performed according to standard Bruce protocol. The exercise test was terminated when 
one or more of the following end points are reached: physical exhaustion, ST-segment 
depression { INCLUDEPICTURE "http://circ.ahajournals.org/math/ge.gif" \* 
MERGEFORMATINET }0.3 mV, or severe arrhythmia. Measurement of interest included 
exercise duration.  
Assessment of Coronary Flow Reserve (CFR) 
Assessment of coronary vascular function were performed out by an experienced 
echocardiographer (TKL) who was blinded to the treatment regimen. Imaging of the left 
anterior descending (LAD) artery or perforating branches and measurement of coronary 
blood flow were carried out using a 7.0 MHz transducer (Acuson Sequoia 512, Siemens 
Medical Solutions, Berkshire, UK). Baseline spectral Doppler signals in the distal portion 
of the LAD coronary artery were recorded over five cardiac cycles at end-expiration. The 
endothelium-independent vasodilator capacity of the coronary microcirculation was 
assessed using spectral Doppler imaging during hyperemic condition following 2 min of 
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intravenous adenosine (140µg/kg/min) infusion. Mean diastolic velocities were 
measured at baseline and at peak hyperemic condition from the Doppler signal 
recordings. These measurements were averaged over three cardiac cycles. For 
adenosine infusion, CFR was defined as the ratio of hyperemic to basal mean diastolic 
velocities. The inter-observer and intra-observer variability for measurement of coronary 
Doppler velocity recordings in our laboratory were 4·9% and 4·0%, respectively. All 
patients had continuous heart rate and ECG monitoring. Blood pressure was recorded at 
baseline and during adenosine infusion, and at recovery.  
Assessment of Peripheral Endothelial Function 
Flow-mediated dilatation of brachial artery 
Flow-mediated vasodilatation (FMD) was assessed with ultrasound imaging of the 
brachial artery with a 15 MHz linear array ultrasound transducer connected to a Hewlett-
Packard Sonos 5500 duplex ultrasound machine before and after a 5-minute occlusion 
of arterial flow in the upper extremity with inflation of a pneumatic cuff to suprasystolic 
pressures. Brachial artery diameter (long axis view) was measured at rest, and during 
peak hyperemia for 2 minutes. Brachial artery diameter measured at its maximum during 
the cardiac cycle with a computer-assisted edge detection system (NIH image analysis 
software). The percent change from baseline diameter to maximum diameter after 
hyperemia will be calculated as an index of flow-mediated vasodilatation in the brachial 
artery. Endothelium-independent vasodilatation was assessed with duplex ultrasound in 
the upper extremity before and 5 minutes after administration of 0.4 mg of sublingual 
nitroglycerin. We have an excellent intra-patient coefficient variation of only 2% in our 
vascular laboratory. 
 
 
Statistical Methods 
Results from  continuous data are shown as mean ± 1 standard deviation. Paired t test 
was used to compare the absolute differences for serum uric acids level, CFR, FMD and 
maximum exercise time before and after high dose of allopurinol/placebo treatment. The 
absolute  percentage differences for serum BNP was obtained using Wilcoxon signed 
ranks test. A p value of < 0·05 (two-sided) was considered significant. Statistical 
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analysis was performed with Analyse-it software for Microsoft excel (Version 1·62, 
Analyse-it software Ltd, Leeds, United Kingdom).  This study was powered for a 20% 
difference in exercise time, based on a previous study in patients with cardiac syndrome 
X { ADDIN EN.CITE { ADDIN EN.CITE.DATA }} with a mean exercise duration of 
517sec and an SD of 114 sec. Power calculations demonstrated that a sample size of 
19.2 will provide a power of 80% to detect a 20% difference in exercise time. This small 
‘proof of concept’ study was not adequately powered to fully assess the effect of 
allopurinol on the discovery measures of CFR, FMD and BNP.  
 
Results 
The clinical characteristics, past medical history and medications are shown in Table 1. 
Of the 19 (11 women & 8 men) cardiac syndrome X participants with mean age 59±10 
years, 12 (63%) have a family history of coronary artery disease and 14 (74%) have a 
history of hypertension and hypercholesterolemia. None of them suffered from diabetes 
based on previous results of serum fasting glucose. Most participants were on anti-
anginal therapy which includes beta-blockers, nitrate or calcium channel blockers. All 
patients completed the study.  
Allopurinol treatment resulted in a significant reduction in serum uric acid levels when 
compared to placebo (-48±24% vs 1·9±11%, p<0·001). However, there was no 
significant difference in maximum exercise time, CFR and FMD between allopurinol and 
placebo treatment arms (Table 2). There was a trend that allopurinol reduced serum 
BNP levels when compared to placebo [-8% (interquartile range -22 to 65%) vs 44% 
(interquartile range -18 to 140%); p= 0·07). 
Noteworthy, there were no adverse effects of treatment reported.  
 
Discussion 
Morbidity of patients with cardiac syndrome X is high and it is associated with continuing 
episodes of chest pain, hospital readmission. Importantly, a history of persistent chest 
pain in these patients has been shown to predict cardiovascular events{ ADDIN 
EN.CITE 
<EndNote><Cite><Author>Johnson</Author><Year>2006</Year><RecNum>4478</Re
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cNum><DisplayText><style face="superscript">9</style></DisplayText><record><rec-
number>4478</rec-number><foreign-keys><key app="EN" db-
id="sde022erm0xppvetvfyv9pv4azzevtattee9" 
timestamp="1491833428">4478</key></foreign-keys><ref-type name="Journal 
Article">17</ref-type><contributors><authors><author>Johnson, 
BD</author><author>Shaw, LJ</author><author>Pepine, CJ</author><author>Reis, 
SE</author><author>Kelsey, SF</author><author>Sopko, G</author><author>Rogers, 
WJ</author><author>Mankad, S</author><author>Sharaf, BL</author><author>Bittner, 
V</author><author>Bairey Merz, CN</author></authors></contributors><auth-
address>Department of Epidemiology, Graduate School of Public Health, University of 
Pittsburgh, PA, USA.</auth-address><titles><title>Persistent chest pain predicts 
cardiovascular events in women without obstructive coronary artery disease: results 
from the NIH-NHLBI-sponsored Women&apos;s Ischaemia Syndrome Evaluation 
(WISE) study</title><secondary-title>Eur Heart J</secondary-
title></titles><periodical><full-title>Eur Heart J</full-title></periodical><pages>1408-
15</pages><volume>27</volume><number>12</number><keywords><keyword>Aged<
/keyword><keyword>Cardiovascular Diseases/ mortality</keyword><keyword>Chest 
Pain/diagnostic imaging/ etiology/mortality</keyword><keyword>Coronary 
Angiography</keyword><keyword>Disease-Free 
Survival</keyword><keyword>Female</keyword><keyword>Follow-Up 
Studies</keyword><keyword>Humans</keyword><keyword>Middle 
Aged</keyword><keyword>Prognosis</keyword><keyword>Risk 
Factors</keyword></keywords><dates><year>2006</year><pub-
dates><date>Jun</date></pub-dates></dates><isbn>0195-668X (Print)&#xD;0195-
668X (Linking)</isbn><accession-num>16720691</accession-
num><urls></urls></record></Cite></EndNote>}. Management of this syndrome 
represents a major challenge to the treating physician and understanding the 
mechanism underlying the condition is of vital importance for patient management. 
Conventional therapies with anti-anginal agents such as nitrates, calcium channel 
antagonists, classic β-adrenoceptor blockers and nicorandil have been tried with 
variable success{ ADDIN EN.CITE 
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<EndNote><Cite><Author>Lim</Author><Year>2009</Year><RecNum>4479</RecNu
m><DisplayText><style face="superscript">10</style></DisplayText><record><rec-
number>4479</rec-number><foreign-keys><key app="EN" db-
id="sde022erm0xppvetvfyv9pv4azzevtattee9" 
timestamp="1491833599">4479</key></foreign-keys><ref-type name="Journal 
Article">17</ref-type><contributors><authors><author>Lim, T. 
K.</author><author>Choy, A. J.</author><author>Khan, F.</author><author>Belch, J. 
J.</author><author>Struthers, A. D.</author><author>Lang, C. 
C.</author></authors></contributors><auth-address>Division of Medicine and 
Therapeutics, University of Dundee, Dundee, UK.</auth-
address><titles><title>Therapeutic development in cardiac syndrome X: a need to target 
the underlying pathophysiology</title><secondary-title>Cardiovasc Ther</secondary-
title></titles><periodical><full-title>Cardiovasc Ther</full-title></periodical><pages>49-
58</pages><volume>27</volume><number>1</number><keywords><keyword>Animal
s</keyword><keyword>Antioxidants/ therapeutic 
use</keyword><keyword>Cardiovascular Agents/ therapeutic 
use</keyword><keyword>Cognitive Therapy</keyword><keyword>Endothelium, 
Vascular/ drug effects/physiopathology</keyword><keyword>Estrogen Replacement 
Therapy</keyword><keyword>Estrogens/deficiency</keyword><keyword>Exercise</ke
yword><keyword>Humans</keyword><keyword>Inflammation/metabolism/physiopathol
ogy/therapy</keyword><keyword>Insulin 
Resistance</keyword><keyword>Microcirculation/drug 
effects</keyword><keyword>Microvascular Angina/ drug 
therapy/metabolism/physiopathology</keyword><keyword>Myocardial 
Ischemia/metabolism/physiopathology/therapy</keyword><keyword>Oxidative Stress/ 
drug effects</keyword><keyword>Treatment 
Outcome</keyword></keywords><dates><year>2009</year><pub-
dates><date>Spring</date></pub-dates></dates><isbn>1755-5914 (Print)&#xD;1755-
5914 (Linking)</isbn><accession-num>19207480</accession-
num><urls></urls></record></Cite></EndNote>}. However, this variable success might 
be related to a failure to target the underlying pathophysiology.  
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Allopurinol is not only a drug that has been used for treatment of gout; it has also been 
previously shown to reduce oxidative stress which is one of the important pathogenesis 
of cardiac syndrome X{ ADDIN EN.CITE 
<EndNote><Cite><Author>Lim</Author><Year>2009</Year><RecNum>4479</RecNu
m><DisplayText><style face="superscript">10</style></DisplayText><record><rec-
number>4479</rec-number><foreign-keys><key app="EN" db-
id="sde022erm0xppvetvfyv9pv4azzevtattee9" 
timestamp="1491833599">4479</key></foreign-keys><ref-type name="Journal 
Article">17</ref-type><contributors><authors><author>Lim, T. 
K.</author><author>Choy, A. J.</author><author>Khan, F.</author><author>Belch, J. 
J.</author><author>Struthers, A. D.</author><author>Lang, C. 
C.</author></authors></contributors><auth-address>Division of Medicine and 
Therapeutics, University of Dundee, Dundee, UK.</auth-
address><titles><title>Therapeutic development in cardiac syndrome X: a need to target 
the underlying pathophysiology</title><secondary-title>Cardiovasc Ther</secondary-
title></titles><periodical><full-title>Cardiovasc Ther</full-title></periodical><pages>49-
58</pages><volume>27</volume><number>1</number><keywords><keyword>Animal
s</keyword><keyword>Antioxidants/ therapeutic 
use</keyword><keyword>Cardiovascular Agents/ therapeutic 
use</keyword><keyword>Cognitive Therapy</keyword><keyword>Endothelium, 
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showed that high dose allopurinol did not have any significant impact in exercise 
capacity on treadmill testing. Allopurinol also had no effect on endothelial function when 
assessed using echocardiographic Doppler derived CRF as well as by FMD of the 
brachial artery. These findings contrast with our previous study that showed that a 
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Limitations 
The present study is relatively small and is likely to be not adequately powered to 
definitively assess the efficacy of allopurinol in patients with cardiac syndrome X. As this 
was a cross-over study, there are potential "carry-over" effects between treatments that 
might have confounded the { HYPERLINK "http://en.wikipedia.org/wiki/Estimates" \o 
"Estimates" } of the { HYPERLINK "http://en.wikipedia.org/wiki/Effect_size" \o "Effect 
size" }. However, we used a 4 weeks wash out period that has been shown to be 
sufficient in our previous published cross-over study using high dose allopurinol{ ADDIN 
EN.CITE 
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num><remote-database-provider>Nlm</remote-database-
provider><language>eng</language></record></Cite></EndNote>}.  
 
Conclusion 
In patients with cardiac syndrome X, we showed that high dose allopurinol did not 
improve exercise capacity, coronary or peripheral endothelial function.  
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Table 1: Clinical Characteristics of Patients 
 
Clinical Characteristics of Patients 
Number of patients: 19 
Mean Age (years): 59 ± 10 
Female: 11 (58%) 
Body mass index (kg/m2): 30 ± 5 
Blood Pressure (mmHg): 142/79 
Heart Rate (beats/min): 70 ± 10 
  
Past Medical History  
Diabetes: 0 (0%) 
Hypertension: 14 (74%) 
Hypercholesterolemia: 14 (74%) 
Family history of coronary artery 
disease: 
12 (63%) 
  
Medications:  
ACE Inhibitors or ARB* (lisinopril 2 (11%) 
  
 {PAGE  } 
or losartan): 
Nitrate (isosorbide mononitrate or 
imdur): 
7 (37%) 
Statin (simvastatin, atorvastatin or 
paravastatin): 
11 (58%) 
Aspirin: 14 (74%) 
Ca channel blockers (amlodipine 
or diltiazem or nifedipine): 
5 (26%) 
Beta blockers (bisoprolol or 
atenolol): 
6 (32%) 
 
Table 2:  Effect of 
Allopurinol on 
Serum Uric acid, 
Endothelial 
Function and 
Exercise time. 
Allopurinol Placebo  
p-value* 
Outcomes Pre 
Treatme
nt 
Post 
Treatme
nt 
Absolut
e 
Differen
ce 
Pre 
Treatment 
Post 
Treatme
nt 
Absolute 
Differenc
e 
Serum Uric Acid 
(mmol/L) 
0.32± 
0.08 
0.17 ± 
0.08 
-0·16 ± 
0·09 
0.32 ± 
0.07 
0.33±0.0
07 
0·01 ± 
0.03 
<0.001 
Serum BNP Level 
(pg/ml) 
6.47 
(3.84 to 
11.2) 
6.28 
(3.39 to 
15.54) 
-8.1% 
(-22 to 
65%) 
6.46 
(4.55 to 
12.5) 
9.53 
(4.04 to 
13.4) 
44.4% 
(-18 to 
140%) 
 
0.07** 
Coronary Flow 
Reserve (ratio) 
3.63 ± 
1.04 
3.66 ± 
0.82 
0·03 ± 
0·71 
3.50 ± 
0.80 
3.62 
±1.03 
0·11 ± 
0·77 
ns 
Flow Mediated 6.98 ± 7.20 ± 0·22 ± 6.64 ±2.84 7.05 0·41 ± ns 
*ARB = angiotensin receptor blocker 
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Vasodilatation (%) 
Endothelium-
dependent 
2.22 2.58 1·40 ±1.62 2·38 
Flow Mediated 
Vasodilatation (%) 
Endothelium-
independent (GTN) 
15.8 
±3.0 
16.0 ± 
4.5 
0·2 ± 2.6 15.5 ± 
3.02 
16.5 ± 
2.5 
1·0 ± 1·6 ns 
Max. Exercise Time 
(mins) 
8.15 ± 
2.43 
8.21 ± 
1.91 
0·06 ± 
1.39 
8.46 ± 
2.15 
8.50 ± 
2.37 
0.03 ± 
0.71 
ns 
   *absolute difference between allopurinol and placebo 
** absolute difference expressed as percentage between allopurinol and placebo 
 
 
 
 
 
Figure 1: Study Flow Chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cardiac Syndrome X with 
positive treadmill stress 
test  
Randomisation 
 
            Pre treatment investigations 
1. Coronary Microvascular function 
 Coronary Flow Reserve 
2. Peripheral Endothelial Function 
 Flow Mediated Dilatation Response 
3. Treadmill Test* 
4. Blood Test 
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600mg Allopurinol for 
6 weeks 
 
Consent, History & 
Examination 
Placebo 
 for 6 weeks 
  
      Post Treatment Investigations 
1. Coronary Microvascular function 
 Coronary Flow Reserve 
2. Peripheral Endothelial Function 
 Flow Mediated Dilatation Response 
3. Treadmill Test* 
4. Blood Test 
 
 
Washout period: 
Participants on 
standard treatment for 
4 weeks 
Cross over to 
alternate 
treatment arm 
*if the difference in exercise 
time is ±15% when 
compared to the baseline 
treadmill test, the treadmill 
test may be repeated so 
that the highest quality of 
data can be obtained 
